Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

DUBLIN, Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020. The presentation is scheduled for 8:30 a.m. PT (11:30 a.m. ET/4:30 p.m. GMT) and may be accessed by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations and Events tab.

Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. Audio replays will be available for 30 days following the presentation.

About Theravance Biopharma

Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.

In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.

We have an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY ELLIPTA. 

For more information, please visit www.theravance.com.

THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies. YUPELRI^® is a United States registered trademark of Mylan Specialty L.P. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:

Jessica Stitt
650-808-4045
investor.relations@theravance.com

Gail Cohen
Corporate Communications
917-214-6603

View original content to download multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-announces-presentation-at-the-38th-annual-jp-morgan-healthcare-conference-300983106.html

SOURCE Theravance Biopharma, Inc.